Literature DB >> 17330854

A review of hypofractionated palliative radiotherapy.

Stephen T Lutz1, Edward L Chow, William F Hartsell, Andre A Konski.   

Abstract

Radiotherapy commonly is employed to address symptoms in patients with symptoms caused by cancer. For this article, the authors reviewed data supporting the use of hypofractionated palliative radiotherapy. In addition to single-fraction treatment for painful bony metastasis, the available literature suggested that courses of 2 to 14 external-beam fractions may provide equivalent relief to longer course treatment in patients with a poor prognosis who have primary cancers of the lung, rectum, bladder, prostate, head and neck, spleen, and gynecologic system. Hypofractionated treatment delivers palliation that is time efficient, cost effective, and minimally toxic. Evidence suggests that the reluctance of radiation oncologists to provide single-fraction treatment acts as a barrier to referrals from palliative care professionals. Collaboration in education, research, and patient advocacy will advance the common objectives of the 2 specialties and lead to an appropriate increase in the use of palliative hypofractionated radiotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17330854     DOI: 10.1002/cncr.22555

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.

Authors:  Danielle Rodin; Bouchra Tawk; Osama Mohamad; Surbhi Grover; Fabio Y Moraes; Mei Ling Yap; Eduardo Zubizarreta; Yolande Lievens
Journal:  Radiother Oncol       Date:  2021-01-14       Impact factor: 6.280

2.  For the fear of doctors: a late presentation of lung cancer.

Authors:  Sheila Oh; Jennifer Gilmore
Journal:  BMJ Case Rep       Date:  2013-08-30

3.  Patients who die during palliative radiotherapy. Status survey.

Authors:  B Berger; H Ankele; M Bamberg; D Zips
Journal:  Strahlenther Onkol       Date:  2014-01-11       Impact factor: 3.621

Review 4.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

5.  Palliative radiotherapy with 1 x 8 Gy using conformal radiotherapy for chemotherapy-refractory, recurrent, aggressive lymphomas.

Authors:  Munetaka Matoba; Kiyotaka Oota; Hisao Tonami; Yasufumi Masaki; Tomouki Sakai; Hisanori Umehara
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

Review 6.  [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?]

Authors:  D Bottke; C Bolenz; S Ott; A Cebulla; T Wiegel
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

7.  Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Authors:  Yi-Hsin Lin; Ming-Chieh Yang; Ssu-Hsueh Tseng; Rosie Jiang; Andrew Yang; Emily Farmer; Shiwen Peng; Talia Henkle; Yung-Nien Chang; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Res       Date:  2018-01-23       Impact factor: 11.151

8.  Non-oncologist Physician Knowledge of Radiation Therapy at an Urban Community Hospital.

Authors:  Evan Siau; Hernando Salazar; Jonathan Livergant; Jonathan Klein
Journal:  J Cancer Educ       Date:  2021-02       Impact factor: 2.037

9.  Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis.

Authors:  Birgitt van Oorschot; Michael Schuler; Anke Simon; Ursula Schleicher; Hans Geinitz
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

10.  Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

Authors:  Gabriella Macchia; Francesco Deodato; Savino Cilla; Francesco Legge; Vito Carone; Vito Chiantera; Vincenzo Valentini; Alessio Giuseppe Morganti; Gabriella Ferrandina
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.